Ablynx already rejected an offer by the Danish group on Dec. 14 and Novo Nordisk said the new bid, made on Dec. 22, was some 14 percent higher. The Belgian company was not immediately available for comment on Monday.
“Novo Nordisk regrets that the board of directors of Ablynx has so far declined to engage in any discussions, despite the proposals which have been put forward,” it said in a statement.
The Danish company said it would pay 28.00 euros per share in cash for Ablynx and an additional 2.50 euros per share if certain conditions related to its research portfolio were met.
Ablynx’s shares have almost doubled in price in the past 12 months, buoyed by successful medical trial data. They closed at 21.20 euros on Friday.
Ablynx specializes in researching novel drugs based on nano-bodies found in the immune systems of llamas and alpacas, for which it partners with several of the world’s largest pharmaceutical firms.
Its products, which are all still undergoing medical trials, target many different diseases such as rheumatoid arthritis, psoriasis or cancer.
An acquisition would be the first by Novo Nordisk CEO Lars Fruergaard Jorgensen, who took over a year ago. He has said the firm needs external innovation to broaden its product line-up.
Novo Nordisk, the world’s biggest diabetes company, has sat out a rash of deal-making that has gripped the rest of the drugs industry in recent years. It has instead focused on its market-leading position making insulin and other diabetes treatments.
In March, the company approached Global Blood Therapeutics (GBT.O), a U.S. biotechnology company focused on serious blood disorders, to discuss a potential takeover.
Tax breaks and other incentives have created a thriving biotech industry in Belgium, with many companies spun off from university projects now listed on the local stock exchange.
Last week, Japan’s Takeda (4502.T) bid 520 million euros for Belgian cell therapy group Tigenix. ($1 = 0.8322 euros)
By Robert-Jan Baratunek
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.